Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

erenumab

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

- PMLiVE

Novartis strengthens autoimmune indications for Cosentyx

Data shows its IL-17A inhibitor can reduce structural disease progression

- PMLiVE

Novartis files CAR-T therapy CTL109 in Europe

Analysts predict Kymriah could become a $1bn-plus product in Europe

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

- PMLiVE

Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

Will go up against Kite Pharma's Yescarta if approved

- PMLiVE

Novartis to buy French radiopharma specialist AAA for $3.9bn

Deal will strengthen its cancer therapy business, says Swiss pharma group

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

- PMLiVE

Lilly mulls divestment of its animal health operations

Pharma firm is due to make a final decision on Elanco in 2018

Novartis Gehry Building

Alcon spin-out more likely but not imminent, says Novartis

A stand-alone company could offer “additional shareholder value”

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Lilly strengthens team with in-house promotions

And two senior leaders retire

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links